Quick Answer
Mereo BioPharma Group plc reported Stockholders Equity of $40.92 million for the year ending 2025.
- Mereo BioPharma Group plc showed a decrease of -32.9% in Stockholders Equity from 2024 to 2025.
- This data is from Mereo BioPharma Group plc's annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $44.40 million | Q2 2023: $49.67 million | Q3 2023: $54.71 million | Q1 2024: $42.84 million | Q2 2024: $78.65 million | Q3 2024: -$72.54 million | Q1 2025: $60.08 million | Q2 2025: $54.18 million | Q3 2025: $46.60 million.
- Over the full 5 years of available data (2021 to 2025), Mereo BioPharma Group plc's Stockholders Equity has declined by 55.6%.
- Historical annual values: Fiscal year 2025: $40.92 million | Fiscal year 2024: $60.97 million | Fiscal year 2023: $50.54 million | Fiscal year 2022: $51.40 million | Fiscal year 2021: $92.20 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: